Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Sunday, November 8, 2026

Back to the front page

From X

@leevalueroach

Lee Roach on X

Clearwater Paper $CLW is a sitting duck for an aggressive activist. Stock is down 30% today. Management has zero at risk capital and all of the shares they own were given to them. No insider buys and only sells. Then this Stanford goofy comes in and buys their Augusta Mill for a ridiculously stupid valuation. He spent shareholders capital at the peak of the cycle for this capex pig at $1,184/ton. This mill has been a problem since day one and now is driving the stock down 30% today because they have to spend even more money on downtime for this POS. And then Mr. Arsen puts this POS in his header on LinkedIn. Only way they can realize value for this is by selling entire company or literally Arsen changing his name to Arson and torching this thing to the ground. The only thing Arsen is doing is torching shareholder capital here. There is no one stopping an activist here imo. Management owns 2% of the shares all from awards. No open market buys from insiders, only sells. Shareholders are visibly unhappy with say on pay support falling four years in a row and 2026 equity pay passed with only 54.5%. There is also no poison pill, all eight seats are up at the 2027 meeting and there is a fat change in control so management will get paid if you can get this dog shit sold. Also bank debt can be prepaid at par and that won't block a buyer. Suzano was exploring a bid in 2024 and Koch/Georgia-Pacific are logical buyers. Idea is to buy all the dog shit $CLW owns and shut it down and it fixes the oversupply in the market. Activist playbook is to buy a big block, flip the board, run a sales process and focus on capital discipline. I think you could sell this for $560/ton which is around $31/share, more than 2x current valuation. Management has blown their entire load on this dumb Augusta facility at the peak and it continues to cost shareholders who have at risk capital money. Management are employees who get paid no matter what happens. Activists should apply here. Fat pitch imo.
@convequity 2 clicks

Convequity on X

The usual explanation for CoreWeave’s credit pressure is that its loans outlast its customer contracts. The filings say otherwise. All of $CRWV’s debt is due before its current contracts end, though only just: $14.6B of notes falls due in 2031-32, as the last contract cash comes in. That distinction matters. For a GPU cloud, debt that outlives its contracts is the dangerous kind. When a contract ends the chips are old, and there is no contract left to borrow against. CoreWeave’s real problem is speed. Each new build needs fresh capital before the last one has paid for itself, and almost all of the debt sits with the parent company. $IREN has the opposite shape. Its Microsoft project loan is matched to the contract. The risk is $6.3B of convertible bonds due 2031-33, mostly after its contracted cash has ended. If IREN’s stock is high by then, bondholders will likely swap the bonds for shares. If it’s low, IREN has to repay them in cash. Which leads to an odd conclusion: slower AI demand growth could help both. Fewer new commitments would give finished projects time to earn back their cost.

Investor Letters

All letters

Post Q3 EVC Update

EVC's Q3 update cites $30 million for a single station, a broadcast-business sale and stronger positioning for 2027.

EVC $832M
Nat Stewart - Stock Picking Newsletter 23 clicks

Entravision Q3 Update

Entravision’s Q3 ad-tech revenue reached $177.2 million, up 133% year over year, while total revenue rose 88% to $226.3 million and diluted…

EVC $832M
The Value Road 4 clicks
TNLIF · long

Trainline PLC

Trainline’s buyback and high free-cash-flow yield support a long thesis.

TNLIF $903M
Value Investors Club 1 click

GREAT DEC-TECTIVE WORK

Diversified Energy reported $255.6 million of “true” nine-month free cash flow, while its $1.8 billion Birch acquisition would shift…

DEC $900M
The Oak Bloke 3 clicks

Problems at Twist Bioscience (TWST)

Twist Bioscience’s $200 rebound followed an Anthropic-linked short squeeze, yet its DNA and protein services face broad competition while…

TWST $8B
Hunterbrook 4 clicks

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 109

YouTube 4

Blogs 15

Seeking Alpha 75 of 279

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

91 accounts
Nominate an account

Investor letters we follow

359 firms

Sectors

Ordered by how often our editor reaches for them.